Which acid‑suppression medication is appropriate for a 10‑year‑old child?

Acid Suppression Medication for a 10-Year-Old Patient

For a 10-year-old child with gastroesophageal reflux disease (GERD), proton pump inhibitors (PPIs) are the first-line acid suppression medications, with omeprazole (0.7-3.3 mg/kg/day), lansoprazole (0.7-3 mg/kg/day), or esomeprazole (0.7-3.3 mg/kg/day) being FDA-approved and most appropriate choices. 1

Recommended First-Line Options

Proton Pump Inhibitors (PPIs)

PPIs are superior to H2 receptor antagonists (H2RAs) for symptom relief and healing of erosive esophagitis in children. 1

For a 10-year-old, the following PPIs are FDA-approved and appropriate:

• Omeprazole: 0.7-3.3 mg/kg/day, administered by sprinkling capsule contents onto soft foods 1

  • FDA-approved for ages 2-16 years 1
  • Effective dosage range demonstrated in clinical trials with improvement in symptoms and esophageal pH monitoring 1

• Lansoprazole: 0.7-3 mg/kg/day 1

  • FDA-approved for ages 1-17 years 1
  • Multiple formulation options: sprinkle capsules on soft foods/juices, strawberry-flavored disintegrating tablets 1
  • Demonstrated healing of all cases of erosive esophagitis in 1-12 year-old children with GERD 1
  • Safe and well-tolerated in children ages 1-11 years at doses of 0.6-1.3 mg/kg/day 2

• Esomeprazole: 0.7-3.3 mg/kg/day 1

  • FDA-approved for ages 1-17 years 1
  • Sprinkle capsule contents onto soft foods 1

Alternative Option: H2 Receptor Antagonists

If PPIs are not appropriate or as an alternative approach:

• Ranitidine: 5-10 mg/kg/day divided in 2-3 doses (peppermint-flavored syrup available) 1

  • FDA-approved for ages 1 month-16 years 1

• Famotidine: 1 mg/kg/day divided in 2 doses (cherry-banana-mint flavored suspension) 1

  • FDA-approved for ages 1-16 years 1

However, H2RAs have significant limitations: 1

• Tachyphylaxis develops within 6 weeks, limiting long-term effectiveness 1
• Less effective than PPIs for symptom relief and healing erosive esophagitis 1
• Acid-inhibiting effects last only approximately 6 hours 1

Important Clinical Considerations

When to Use Acid Suppression

Reserve acid suppression medications for children with proven erosive esophagitis or GERD causing significant symptoms affecting quality of life and growth. 3

Avoid empirical treatment without proper diagnosis, as evidence shows questionable efficacy and increased infection risks. 3, 4

Treatment Duration and Monitoring

• Initial trial: 2 weeks of PPI therapy 1
• If symptoms improve: Continue for 8-12 weeks 1
• If no improvement after 2 weeks: Reassess diagnosis before increasing dose or changing medications 1
• Frequently re-evaluate treatment need to minimize risks of ongoing therapy 3

Safety Concerns and Adverse Effects

PPIs are generally safe and well-tolerated but carry potential risks: 1

• Common adverse effects (up to 14%): headaches, diarrhea, constipation, nausea 1
• Increased fasting serum gastrin levels (though typically remain within normal range) 2
• Growing evidence suggests increased risk of serious infections: 1, 4
  • Community-acquired pneumonia 1
  • Gastroenteritis 1
  • Candidemia 1
• Enterochromaffin cell hyperplasia in up to 50% of children receiving PPIs for more than 2.5 years 1

Medications to Avoid

Avoid cimetidine specifically due to increased risk of liver disease and gynecomastia. 1

Do not routinely use prokinetic agents (metoclopramide, domperidone) as there is insufficient evidence to support their use and significant adverse effects including extrapyramidal reactions. 1

Clinical Algorithm

1. Confirm diagnosis of GERD (not just physiologic reflux) with appropriate symptoms and/or diagnostic testing
2. Start with lifestyle modifications and non-pharmacologic interventions first
3. If medication needed, initiate PPI:
   • Lansoprazole 0.7-3 mg/kg/day OR
   • Omeprazole 0.7-3.3 mg/kg/day OR
   • Esomeprazole 0.7-3.3 mg/kg/day
4. Assess response at 2 weeks:
   • If improved: Continue for 8-12 weeks total 1
   • If not improved: Reassess diagnosis before escalating therapy 1
5. After treatment course, attempt to discontinue and monitor for relapse 1
6. If relapse occurs, consider gastroenterology consultation 1